Llwytho...
Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus
BACKGROUND: Given the modest responses to everolimus, a mTOR inhibitor, in multiple tumor types, there is a pressing need to identify predictive biomarkers for this drug. Using targeted ultra-deep sequencing, we aimed to explore genomic alterations that confer extreme sensitivity to everolimus. RESU...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Oncotarget |
|---|---|
| Prif Awduron: | , , , , , , , , , , , , , , , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Impact Journals LLC
2016
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4891139/ https://ncbi.nlm.nih.gov/pubmed/26859683 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.7234 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|